Insider Selling: United Therapeutics Co. (NASDAQ:UTHR) CFO Sells $2,771,078.76 in Stock

United Therapeutics Co. (NASDAQ:UTHR) CFO James Edgemond sold 7,794 shares of the business’s stock in a transaction that occurred on Monday, October 7th. The stock was sold at an average price of $355.54, for a total value of $2,771,078.76. Following the completion of the transaction, the chief financial officer now directly owns 5,344 shares in the company, valued at approximately $1,900,005.76. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

James Edgemond also recently made the following trade(s):

• On Monday, September 30th, James Edgemond sold 7,792 shares of United Therapeutics stock. The shares were sold at an average price of $358.62, for a total transaction of $2,794,367.04.
• On Monday, September 23rd, James Edgemond sold 7,796 shares of United Therapeutics stock. The stock was sold at an average price of $354.04, for a total transaction of $2,760,095.84.
• On Monday, September 9th, James Edgemond sold 7,802 shares of United Therapeutics stock. The shares were sold at an average price of $345.41, for a total transaction of $2,694,888.82.
• On Tuesday, September 3rd, James Edgemond sold 7,785 shares of United Therapeutics stock. The shares were sold at an average price of $362.37, for a total transaction of $2,821,050.45.

United Therapeutics Trading Down 0.7 %

Shares of UTHR opened at $354.33 on Friday. United Therapeutics Co. has a 1-year low of $208.62 and a 1-year high of $366.08. The firm has a market capitalization of $15.72 billion, a price-to-earnings ratio of 16.75, a PEG ratio of 1.29 and a beta of 0.57. The company has a 50-day moving average of $346.12 and a 200 day moving average of $302.60. The company has a debt-to-equity ratio of 0.02, a current ratio of 4.35 and a quick ratio of 4.18.

United Therapeutics (NASDAQ:UTHR) last posted its earnings results on Wednesday, July 31st. The biotechnology company reported $5.85 EPS for the quarter, missing analysts’ consensus estimates of $6.33 by ($0.48). The business had revenue of $714.90 million for the quarter, compared to analysts’ expectations of $691.87 million. United Therapeutics had a net margin of 40.87% and a return on equity of 18.82%. The company’s revenue for the quarter was up 19.8% on a year-over-year basis. During the same period last year, the business posted $5.24 EPS. On average, research analysts expect that United Therapeutics Co. will post 24.71 EPS for the current year.

Analyst Upgrades and Downgrades

A number of brokerages recently commented on UTHR. LADENBURG THALM/SH SH lowered United Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Thursday, August 1st. TD Cowen increased their target price on United Therapeutics from $270.00 to $350.00 and gave the company a “buy” rating in a research report on Thursday, July 11th. UBS Group boosted their price target on shares of United Therapeutics from $300.00 to $370.00 and gave the stock a “buy” rating in a research report on Monday, July 8th. Bank of America lowered their price objective on shares of United Therapeutics from $303.00 to $280.00 and set an “underperform” rating for the company in a research report on Thursday, August 1st. Finally, HC Wainwright reissued a “buy” rating and issued a $400.00 price objective on shares of United Therapeutics in a research note on Thursday, August 1st. One research analyst has rated the stock with a sell rating, three have given a hold rating and eleven have issued a buy rating to the stock. Based on data from MarketBeat, United Therapeutics currently has an average rating of “Moderate Buy” and an average target price of $357.17.

Institutional Trading of United Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in the business. Renaissance Technologies LLC boosted its holdings in United Therapeutics by 1.1% in the second quarter. Renaissance Technologies LLC now owns 2,174,692 shares of the biotechnology company’s stock worth $692,748,000 after acquiring an additional 22,978 shares in the last quarter. LSV Asset Management increased its holdings in shares of United Therapeutics by 82.5% in the second quarter. LSV Asset Management now owns 966,370 shares of the biotechnology company’s stock valued at $307,837,000 after purchasing an additional 436,851 shares during the period. Dimensional Fund Advisors LP raised its position in United Therapeutics by 4.0% during the 2nd quarter. Dimensional Fund Advisors LP now owns 585,969 shares of the biotechnology company’s stock worth $186,656,000 after buying an additional 22,683 shares during the last quarter. Pacer Advisors Inc. boosted its holdings in shares of United Therapeutics by 19.6% in the 2nd quarter. Pacer Advisors Inc. now owns 561,834 shares of the biotechnology company’s stock valued at $178,972,000 after acquiring an additional 92,240 shares during the last quarter. Finally, Swedbank AB purchased a new stake in United Therapeutics in the first quarter valued at $97,316,000. Hedge funds and other institutional investors own 94.08% of the company’s stock.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.